Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 134,986 251,929 319,053 656,089
Total Sell Value $11,097,511 $21,508,551 $27,661,182 $61,420,002
Total People Sold 5 6 7 7
Total Sell Transactions 9 19 27 56
End Date 2024-04-04 2024-01-02 2023-07-04 2022-07-04

   
Records found: 1285
  Page 33 of 52  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Mueller Brian SVP, Corporate Controller   •       –      –    2017-06-22 4 AS $100.00 $267,100 D/D (2,671) 12,885     -
   Mueller Brian SVP, Corporate Controller   •       –      –    2017-06-22 4 OE $21.51 $57,453 D/D 2,671 15,556     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2017-06-19 4 AS $90.00 $54,270 D/D (603) 136,422     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2017-06-19 4 OE $37.46 $22,588 D/D 603 137,025     -
   Lawlis V Bryan Director   –       •      –    2017-06-16 4 AS $90.00 $337,500 D/D (3,750) 15,910     -
   Lawlis V Bryan Director   –       •      –    2017-06-16 4 OE $38.59 $144,713 D/D 3,750 19,660     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2017-06-16 4 AS $90.00 $1,295,730 D/D (14,397) 136,422     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2017-06-16 4 OE $26.49 $484,462 D/D 14,397 150,819     -
   Davis George Eric EVP, General Counsel   •       –      –    2017-06-09 4 OE $21.51 $217,530 D/D 9,239 83,581     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2017-06-07 4 AS $89.61 $89,968 D/D (1,004) 47,944     -
   Lawlis V Bryan Director   –       •      –    2017-06-06 4 A $0.00 $0 D/D 2,050 15,910     -
   Pyott David E I Director   –       •      –    2017-06-06 4 A $0.00 $0 D/D 2,050 4,910     -
   Lewis Alan Director   –       •      –    2017-06-06 4 A $0.00 $0 D/D 2,050 26,060     -
   Slamon Dennis Director   –       •      –    2017-06-06 4 A $0.00 $0 D/D 2,050 9,885     -
   Grey Michael G Director   –       •      –    2017-06-06 4 A $0.00 $0 D/D 2,050 29,810     -
   Meier Richard A Director   –       •      –    2017-06-06 4 A $0.00 $0 D/D 2,050 36,310     -
   Heron Elaine J Director   –       •      –    2017-06-06 4 A $0.00 $0 D/D 2,050 39,185     -
   Dere Willard H Director   –       •      –    2017-06-06 4 A $0.00 $0 D/D 2,050 4,690     -
   Davis George Eric EVP, General Counsel   •       –      –    2017-06-05 4 S $91.04 $862,230 D/D (9,471) 74,342     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-06-05 4 AS $90.56 $452,800 D/D (5,000) 226,924     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2017-06-05 4 OE $17.33 $86,650 D/D 5,000 231,924     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2017-06-02 4 D $90.72 $163,387 D/D (1,801) 23,303     -
   Mueller Brian SVP, Corporate Controller   •       –      –    2017-06-02 4 D $90.72 $34,111 D/D (376) 12,885     -
   Fuchs Henry J President, Worldwide R&D   •       –      –    2017-06-02 4 D $90.72 $184,706 D/D (2,036) 136,422     -
   Ajer Jeffrey Robert EVP, Chief Commercial Officer   •       –      –    2017-06-02 4 D $90.72 $134,991 D/D (1,488) 48,948     -
  1285 Records found
  Previous  30  31  32  33  34  35  36  37  38  39  Next   
  Page 33 of 52
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us